Featured News

George Washington's Vaccine Research Unit is participating in the Project NextGen clinical study. Read this article on the journey to preparing the vaccines and treatments for the next outbreak.
Read more information about how The George Washington Vaccine Research Unit is looking for adolescents between the ages of 12 and 17 to participate in a Mpox vaccine trial. The need for adolescents is vital for researchers to get an approved vaccine for adolescents to prevent another outbreak.
Here is more information about the NIH trials and what Dr. Diemert and other infectious disease experts have to say about the progress in the monkeypox vaccine.
Check out this interview with our very own Dr. Diemert, the director of the GW Vaccine Research Unit on WTOP to learn more about our current monkeypox trial.
NIH Trial is Evaluating Intradermal Delivery to Expand the Vaccine Supply.
Dr. Diemert and other infectious disease experts discuss the search for a universal COVID-19 vaccine and comparisons to the seasonal influenza vaccine.
Doreen Gentzler, NBC4 News Anchor, interviews GW VRU Director, Dr. David Diemert on monkeypox myths and facts.
Long-awaited protection for tots appears close to arrival. Moderna also get clearance for vaccine for 6- to 17-year olds.
How is the shot different from Pfizer, Moderna and J&J? Does it work against new variants? Here's what to know.
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron…